Related Experiment Video
Updated: Jul 7, 2026
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Targeting CD162 for Life-Threatening Cutaneous Chronic Graft-Versus-Host Disease: A Case Report
Alicia Lieberman1, Ross McCauley1, Maureen Ross1
1Roswell Park Comprehensive Cancer Center Transplant and Cell Therapy Program Buffalo New York USA.
None:
Steroid-refractory chronic cutaneous graft-versus-host disease (GVHD) causes substantial morbidity, prolonged hospitalization, and non-relapse mortality after allogeneic hematopoietic cell transplantation. We report a young adult with multisystem chronic GVHD and recurrent life-threatening inflammatory skin flares refractory to multiple standard therapies, with cumulative inpatient care exceeding 1 year. Under an institutional review board-approved compassionate-use protocol, he received a non-cytotoxic monoclonal antibody targeting CD162 (P-selectin glycoprotein ligand-1). Treatment was associated with durable resolution of active cutaneous GVHD, corticosteroid reduction, improved mobility, and meaningful recovery in daily function and quality of life.
Trial Registration:
The author has confirmed clinical trial registration is not needed for this submission.
